These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 3542946

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparative in vitro studies with 4-quinolone antimicrobials.
    Felmingham D, O'Hare MD, Robbins MJ, Wall RA, Williams AH, Cremer AW, Ridgway GL, Grüneberg RN.
    Drugs Exp Clin Res; 1985; 11(5):317-29. PubMed ID: 2941259
    [Abstract] [Full Text] [Related]

  • 4. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
    Bassey CM, Baltch AL, Smith RP.
    J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In-vitro activity of newer quinolones against aerobic bacteria.
    Auckenthaler R, Michéa-Hamzehpour M, Pechère JC.
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Mechanisms of action of and resistance to ciprofloxacin.
    Hooper DC, Wolfson JS, Ng EY, Swartz MN.
    Am J Med; 1987 Apr 27; 82(4A):12-20. PubMed ID: 3034057
    [Abstract] [Full Text] [Related]

  • 12. In vitro susceptibility of aerobic gram-negative blood culture isolates to oxolinic acid, norfloxacin, ciprofloxacin, enoxacin, pefloxacin, ofloxacin and oxo-enoxacin.
    Van der Auwera P.
    Infection; 1986 Apr 27; 14(3):142-4. PubMed ID: 2942489
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Membrane permeability of Pseudomonas aeruginosa to 4-quinolones.
    Kubesch P, Wehsling M, Tümmler B.
    Zentralbl Bakteriol Mikrobiol Hyg A; 1987 Jun 27; 265(1-2):197-202. PubMed ID: 3118593
    [Abstract] [Full Text] [Related]

  • 15. [Gyrase inhibitor].
    Forth W.
    Klin Wochenschr; 1985 Oct 01; 63(19):1036-9. PubMed ID: 2999503
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis.
    Berlin OG, Young LS, Bruckner DA.
    J Antimicrob Chemother; 1987 May 01; 19(5):611-5. PubMed ID: 3112095
    [Abstract] [Full Text] [Related]

  • 18. [In vitro activity of new quinolones against nonfermenters and references to sensitivity tests].
    Grimm H.
    Infection; 1986 May 01; 14 Suppl 3():S191-5. PubMed ID: 3093387
    [Abstract] [Full Text] [Related]

  • 19. [In vitro activity of new quinolones against Mycoplasma pathogenic to humans].
    Renaudin H, Quentin C, de Barbeyrac B, Bebear C.
    Pathol Biol (Paris); 1988 May 01; 36(5):496-9. PubMed ID: 3136430
    [Abstract] [Full Text] [Related]

  • 20. [Refractory respiratory tract infections. 7. Trends in the development of new chemotherapeutic agents for respiratory tract infections. b. Synthetic antibacterial agents].
    Ohno I, Ida S.
    Nihon Rinsho; 1987 Mar 01; 45(3):577-82. PubMed ID: 3298736
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.